Palisade Bio Inc. Stock
Palisade Bio Inc. Stock
Our community is currently high on Palisade Bio Inc. with 5 Buy predictions and 1 Sell predictions.
With a target price of 21 € there is potential for a 6054.75% increase which would mean more than doubling the current price of 0.34 € for Palisade Bio Inc..
Our community identified positive and negative aspects for Palisade Bio Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Palisade Bio Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | -2.530% | -4.309% | -14.549% | -51.583% | 19.808% | -61.034% | -94.244% |
| Pacira Pharmaceuticals | - | 7.650% | 11.299% | -17.917% | -8.796% | -47.884% | -68.226% |
| Twist Bioscience Corp | -4.630% | -0.218% | 7.262% | 4.276% | 47.971% | 109.870% | -63.531% |
Comments
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat